Alpha Cognition Inc. has reported its financial results for the first quarter ending March 31, 2025. The company announced net product revenues for ZUNVEYL of $347 thousand for the quarter. Additionally, Alpha Cognition secured licensing revenue amounting to $2.6 million for the same period, reflecting their partnership with CMS Pharma. The company experienced a reduction in research and development expenses, which were $408 thousand for the first quarter of 2025, compared to $917 thousand for the same period in 2024. However, selling, general, and administrative expenses increased to $5.4 million from $3.5 million in the first quarter of the previous year, primarily driven by commercial-readiness activities. The net loss for the quarter was $2.0 million, an improvement from the $5.0 million net loss reported for the same period in 2024. Cash and cash equivalents were reported at $45.5 million as of March 31, 2025, down from $48.6 million as of December 31, 2024. The company expects its current cash runway to sustain operations for approximately two years. Significant business and operational highlights include the successful launch of ZUNVEYL to the U.S. long-term care market. The product has received positive early market feedback, highlighting its impact on cognitive function and its established safety profile. Medicare reimbursement was secured shortly after the launch, enhancing access for long-term care patients. The company also strengthened its intellectual property portfolio with a new composition of matter patent for benzgalantamine, extending U.S. protection through 2044 and global protection through 2041. Additionally, an extension of a method of use patent is expected to be finalized by the FDA in Q3 2025.